Print page
Email page
Download PDF
« Previous Release | Next Release »
COLUMBIA, Md., Nov 17, 2008 (BUSINESS WIRE) --
Celsion Corporation (NASDAQ: CLSN), a biotechnology drug development company that is leveraging its Heat Sensitive Liposomal Technology platform to encapsulate and deliver high concentrations of proven chemotherapeutics, today announced that President and CEO Michael H. Tardugno will present at BIO-Europe 2008 in Mannheim, Germany on November 18, 2008. This year marks BIO-Europe's 14th Annual International Partnering Conference, with over 1,300 global companies represented. The presentation is scheduled to begin at 10:30 a.m. CET at the m:con Congress Center Rosengarten.
About Celsion
Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, and North Shore Hospital.
For more information on Celsion, visit: http://www.celsion.com.
SOURCE: Celsion Corporation
FD
Geoff Grande, +1-617-747-1721
geoff.grande@fd.com
Copyright Business Wire 2008
News Provided by COMTEX
